• mAbxience will hold the marketing authorization, while Abiogen Pharma will manage commercialization and marketing activities in Italy.
• This partnership combines mAbxience’s expertise in biosimilar development with Abiogen Pharma’s strong presence and commercial capabilities in the Italian market.

Madrid, Spain, May 26^th, 2025 — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Abiogen Pharma today announced a new strategic licensing agreement to develop and commercialize a biosimilar candidate in Italy.

Under the terms of this agreement, mAbxience will hold the marketing authorization for the biosimilar candidate, while Abiogen Pharma will be responsible for all commercialization and marketing activities in Italy. This collaboration combines mAbxience’s expertise in biosimilar development with Abiogen Pharma’s strong presence and commercial capabilities in the Italian market.

“We are thrilled to partner with Abiogen Pharma to bring this biosimilar candidate to patients in Italy. Our collaboration reflects mAbxience’s commitment to delivering high-quality, accessible therapies across various geographies,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.

“This agreement is part of a broader, long-term strategic path for us,” said Prisca Di Martino, Chief Commercial Officer at Abiogen Pharma. “It reflects our dedication to therapeutic areas where we bring deep expertise. Partnering with mAbxience supports our goal to expand access to advanced biologic therapies in Italy. This is another step towards innovative, sustainable solutions for patients and healthcare systems.”

This agreement marks another milestone in mAbxience’s strategy to provide affordable, life-saving therapies worldwide. Both mAbxience and Abiogen Pharma expect that this partnership will enhance patient access to advanced treatments, while also helping healthcare systems manage the rising costs of biologic therapies.